PORT WASHINGTON, NY — Pall Corporation (NYSE: PLL), a global leader in filtration, separation and purification, has introduced Pall T-Series cassettes for use in tangential flow filtration (TFF) applications. The new cassettes feature significant design enhancements while utilizing the same proven membranes to reduce revalidation requirements.

T-series cassettes have been designed with more durable and stable materials, which exhibit low extractables and offer broad chemical compatibility to increase process safety, reliability and reproducibility. Additional design improvements maximize mass transfer at the membrane surface, resulting in faster processing times or reduced area installations compared to existing similar cassette formats. Larger feed and permeate ports provide lower pressure drops.

The new cassettes are available with Omega™ polyethersulfone (PES) or Delta regenerated cellulose membrane for high flux, high selectivity and low protein binding in a range of biological and biopharmaceutical processes. Omega PES membranes have been modified specifically to minimize protein binding to the surface and interstitial structure of the membrane. These membranes are ideal for use in vaccine and conjugate concentration and diafiltration, purification and recovery of monoclonal antibodies or recombinant proteins, and blood plasma fractionation and purification.

Delta regenerated cellulose membrane delivers low fouling characteristics to allow consistent performance or flux from run to run. Delta membrane is easy to clean and is useful when working with antibody fragments, and in the purification and recovery of antibodies.

“The T-Series has been highly anticipated because of its potential to increase process performance while lowering process costs,” said Thomas Scholz, global product manager of TFF products, Pall Life Sciences. “By incorporating the same high-performance membranes, we make it easy for current customers to implement the new cassettes into their processes. Both current and new users will appreciate the advantages of the new cassette design.”

Scalable T-Series cassettes are compatible with Pall’s Centramate™ and Centrasette™ systems. T-Series cassettes for Centramate holders are offered in membrane formats with effective filtration areas (EFA) from as low as 86 cm2 (0.09 ft2), making them ideal for process development and small-scale production of 50 mL to 125 L. In combination with Centrasette holders, T-Series cassettes can process thousands of liters with installations incorporating hundreds of square meters of EFA.

Each T-Series membrane cassette has a unique serial number for full traceability and is supplied with a certificate of quality, care and use procedures, a material safety data sheet for the cassette preservative, and two platinum-cured silicone gaskets. The full validation guide is available on request, and Pall’s Downstream Processing Specialists are available to train and support customers in the optimization of their TFF processes.

Pall T-Series cassettes are part of the company’s UpScaleSM Program, which provides the most comprehensive family of scalable filtration, separation and chromatography products.

T-Series cassettes are available through Pall Life Sciences and can be ordered by phone at 800-717-7255 in the U.S. or +41 (0)26 350 53 00 in Europe. For a complete listing of international offices, visit Pall online at www.pall.com/contact.

Pall Life Sciences provides cutting-edge products and services to meet the demanding needs of customers discovering, developing and producing biotech drugs, vaccines and classic pharmaceuticals. Pall technologies are also used to collect and process blood components and help protect patients from hospital-acquired infections. The company’s membranes and membrane devices optimize detection and sample preparation in the drug research, clinical diagnostics, genomics, and proteomics markets. Pall is a leading provider of separation systems and single-use filtration and purification technologies to pharmaceutical and biotechnology companies to support faster development of new drugs and vaccines that are safer and require less energy and water to produce.

About Pall Corporation

Pall Corporation (NYSE:PLL) is a filtration, separation and purification leader providing Total Fluid ManagementSM solutions to meet the critical needs of customers in biopharmaceutical; hospital, transfusion and veterinary medicine; energy and alternative energy; electronics; municipal and industrial water; aerospace; transportation and broad industrial markets. Together with our customers, we foster health, safety and environmentally responsible technologies. The Company’s engineered solutions enable process and product innovation and minimize emissions and waste. Pall Corporation, with total revenues of $2.3 billion for fiscal 2009, is an S&P 500 company with more than 10,000 employees servicing customers worldwide. Pall has been named a top “green company” by Newsweek magazine. To see how Pall is helping enable a greener and more sustainable future, visit www.pall.com.